<DOC>
	<DOCNO>NCT02709655</DOCNO>
	<brief_summary>Investigation efficacy safety new potential treatment Major depressive disorder ( MDD ) paediatric patient ( age 7 11 year )</brief_summary>
	<brief_title>Active Reference ( Fluoxetine ) Fixed-dose Study Vortioxetine Paediatric Patients Aged 7 11 Years With Major Depressive Disorder ( MDD )</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Vortioxetine</mesh_term>
	<mesh_term>Fluoxetine</mesh_term>
	<criteria>1 . The patient Major depressive disorder ( MDD ) , diagnose accord DSM5™ . 2 . The patient CDRSR total score ≥45 Screening Visit Baseline . 3 . The patient Clinical Global Impression Severity Illness ( CGIS ) score ≥4 Screening Visit Baseline . 4 . The patient boy girl , age ≥7 &lt; 12 year Screening Visit 5 . The patient provide assent participation parent ( ) /legal representative ( ) sign Informed Consent Form . 1 . The patient participate clinical study &lt; 30 day prior Screening Visit . 2 . The patient previously participate study vortioxetine . Other protocol define inclusion exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>paediatric</keyword>
</DOC>